Single cycle replicating adenovirus vectors

Patent metadata

Field	Value
Publication number	US-10640786-B2
Application number	US-201916570535-A
Country	US
Kind code	B2
Filing date	Sep 13, 2019
Priority date	Mar 6, 2008
Publication date	May 5, 2020
Grant date	May 5, 2020

Abstract

This document relates to adenovirus vectors and methods and materials related to using adenovirus vectors. For example, viruses, nucleic acid molecules encoding viruses, cell lines containing viral vectors, and methods for using viruses to deliver nucleic acid to cells in vitro or in vivo are provided. Methods and materials for using adenovirus vectors to induce immune responses and to treat cancer also are provided.

First claim

What is claimed is:

1. A method for inducing an immune response against an antigen in a mammal, wherein said method comprises administering a single cycle replicating adenovirus to said mammal under conditions wherein said adenovirus infects a cell of said mammal and replicates within said cell, wherein said cell does not produce new infectious virions following infection with said adenovirus, wherein said adenovirus comprises an adenovirus polypeptide and lacks at least a portion of a nucleic acid sequence that encodes said adenovirus polypeptide, wherein when said adenovirus lacks at least a portion of a nucleic acid sequence that encodes a fiber protein, said adenovirus comprises a fiber protein having wild-type specificity, wherein said adenovirus comprises a nucleic acid sequence encoding said antigen, and wherein expression of said antigen in said cell leads to induction of said immune response.

2. The method of claim 1 , wherein said mammal is a human.

3. The method of claim 1 , wherein said antigen is a tumor antigen.

4. The method of claim 3 , wherein said tumor antigen is NY-ESO, EBV-LMP, or a papilloma virus antigen.

5. The method of claim 1 , wherein said cell is an epithelial cell, a tumor cell, a hematopoietic cell, or an antigen presenting cell.

6. The method of claim 1 , wherein said adenovirus polypeptide is a fiber protein, a V protein, hexon, penton-base, or pIII.

7. A method for delivering a therapeutic polypeptide to a mammal, wherein said method comprises administering a single cycle replicating adenovirus to said mammal under conditions wherein said adenovirus infects a cell of said mammal and replicates within said cell, wherein said cell does not produce new infectious virions following infection with said adenovirus, wherein said adenovirus comprises an adenovirus polypeptide and lacks at least a portion of a nucleic acid sequence that encodes said adenovirus polypeptide, wherein when said adenovirus lacks at least a portion of a nucleic acid sequence that encodes a fiber protein, said adenovirus comprises a fiber protein having wild-type specificity, wherein said adenovirus comprises a nucleic acid sequence encoding said therapeutic polypeptide.

8. The method of claim 7 , wherein said mammal is a human.

9. The method of claim 7 , wherein said therapeutic polypeptide is a thymidine kinase, a fusogenic glycoprotein, a tumor suppressor p53, a heat shock protein polypeptide.

10. The method of claim 7 , wherein said cell is a tumor cell, a hematopoietic cell, a liver cell, or a gastrointestinal cell.

11. The method of claim 7 , wherein said adenovirus polypeptide is a fiber protein, a V protein, hexon, penton-base, or pIII.

Assignees

• Mayo Found Medical Education & Res

Inventors

• Barry Michael A
• Weaver Eric

Classifications

• C12N15/86 Primary

  Viral vectors · CPC title

• C12N2710/10343

  viral genome or elements thereof as genetic vector · CPC title

• A61K2039/542

  oral/gastrointestinal · CPC title

• A61K39/12

  Viral antigens · CPC title

• A61P37/04

  Immunostimulants · CPC title